Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nathanael Gray
New York University School of Medicine, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Syros
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Syros licensed a cyclin- dependent kinase 7 (CDK7) inhibitor developed in Dr. Gray’s laboratory at DFCI. Syros aims to understand the non-coding region of the genome to advance new medicines that control expression of disease-driving genes. According to publicly available information, Syros has built a proprietary platform designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations, including CDK inhibitors. Syros is currently focused on cancer and immune-mediated diseases and is advancing the following lead drug candidates: (i) SY-1425, a selective RARα agonist; and (ii) SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. The company also recently announced that it is advancing four preclinical programs, including the oral CDK7 inhibitor program and its cyclin-dependent kinase 12/13 (CDK12/13) inhibitor program. The proposed project aims to investigate the therapeutic potential of CDK inhibitors for broadly targeting transcriptional and epigenetic dependencies in chemo-refractory small cell lung cancer (SCLC). The Dana-Farber Cancer Institute Conflict of Interest Committee concluded that the results of this research could be of scientific and financial interest to Syros and, accordingly, represented a financial conflict of interest under the regulations.
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer
Narrative Small Cell Lung Cancer (SCLC) rapidly develops resistance to first-line chemotherapy. There are currently no treatment options for patients with chemo-refractory disease leading to a very poor prognosis. Building on promising initial results in preclinical SCLC models, this proposal aims to investigate the therapeutic potential of CDK inhibitors for broadly targeting transcriptional and epigenetic dependencies in chemo-refractory SCLC.
Filed on September 18, 2017.
Tell us what you know about Nathanael Gray's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nathanael Gray filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $80,000 - $99,999 |
| Nathanael Gray | New York University School of Medicine | Conflict of Interest | Syros | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | $60,000 - $79,999 |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | Petra Pharmaceuticals | Value cannot be readily determined |
| Nathanael Gray | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.